 The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome ACS and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction heart attack, repeat myocardial infarctions, stroke, and ischemia inadequate blood supply to a local area in patients with recent ACS. 